Press Releases

20 September 2022

Coave Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

Read more
12 September 2022

Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders

Read more
6 September 2022

Coave Therapeutics Strengthens Leadership Team with the Appointments of Catherine Mathis as Vice President Regulatory Affairs and Julien Berger as Head of Legal Affairs

Read more
29 June 2022

Coave Therapeutics Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Next-generation Gene Therapies Targeting CNS Diseases

Read more
9 June 2022

Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based gene therapy

Read more
3 May 2022

Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

Read more
27 April 2022

Coave Therapeutics will be presenting an abstract at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held in Denver, Colorado 1-4 May 2022. The meeting will also be available for virtual attendees 11-12 May.

Read more
13 April 2022

Coave Therapeutics to Present at Cell & Gene Meeting on the Mediterranean

Read more
15 November 2021

Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer

Read more
12 October 2021

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

Read more
WordPress Cookie Plugin by Real Cookie Banner